About: The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response
Creator	Wei, Haiming Montesarchio, Vincenzo Arnaldez, Fernanda Ascierto, Paolo Drake, Charles Fox, Bernard Fu, Bingqing O'day, Steven Urba, Walter Weber, Jeffrey Wigginton, Jon
Source	Medline; PMC
abstract	The pandemic caused by the novel coronavirus SARS-CoV-2 has placed an unprecedented burden on healthcare systems around the world. In patients who experience severe disease, acute respiratory distress is often accompanied by a pathological immune reaction, sometimes referred to as ‘cytokine storm’. One hallmark feature of the profound inflammatory state seen in patients with COVID-19 who succumb to pneumonia and hypoxia is marked elevation of serum cytokines, especially interferon gamma, tumor necrosis factor alpha, interleukin 17 (IL-17), interleukin 8 (IL-8) and interleukin 6 (IL-6). Initial experience from the outbreaks in Italy, China and the USA has anecdotally demonstrated improved outcomes for critically ill patients with COVID-19 with the administration of cytokine-modulatory therapies, especially anti-IL-6 agents. Although ongoing trials are investigating anti-IL-6 therapies, access to these therapies is a concern, especially as the numbers of cases worldwide continue to climb. An immunology-informed approach may help identify alternative agents to modulate the pathological inflammation seen in patients with COVID-19. Drawing on extensive experience administering these and other immune-modulating therapies, the Society for Immunotherapy of Cancer offers this perspective on potential alternatives to anti-IL-6 that may also warrant consideration for management of the systemic inflammatory response and pulmonary compromise that can be seen in patients with severe COVID-19.
has issue date	2020-05-07(xsd:dateTime)
bibo:doi	10.1136/jitc-2020-000930
bibo:pmid	32385146
has license	cc-by-nc
sha1sum (hex)	7e069f15cd849adb1d95c5146fa8b2eb00162820
schema:url	https://doi.org/10.1136/jitc-2020-000930
resource representing a document's title	The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response
has PubMed Central identifier	PMC7211108
has PubMed identifier	32385146
schema:publication	J Immunother Cancer
resource representing a document's body	covid:7e069f15cd849adb1d95c5146fa8b2eb00162820#body_text
is schema:about of	named entity 'interleukin-6' named entity 'chronic conditions' named entity 'signaling cascades' named entity 'FDA' named entity 'COVID' named entity 'pathology' named entity 'Actemra' named entity 'pulmonary alveolar proteinosis' named entity 'clinical features' named entity 'Janus kinase' named entity 'pathology' named entity 'pneumonia' named entity 'randomized trials' named entity 'double-blind, placebo-controlled' named entity 'Stelara' named entity 'isoform' named entity 'Istituto Nazionale' named entity 'GSK' named entity 'cytokine' named entity 'CRS' named entity 'acute phase protein' named entity 'ARDS' named entity 'COVID-19' named entity 'nausea' named entity 'IL-12' named entity 'kDa' named entity 'infection' named entity 'IL-6R' named entity 'SJO' named entity 'TNFα' named entity 'IFNγ' named entity 'cytokine storm' named entity 'pulmonary toxicity' named entity 'CAR T cells' named entity 'refractory' named entity 'IL-1RA' named entity 'high-risk' named entity 'AEs' named entity 'ICU' named entity 'psoriatic arthritis' named entity 'COVID-19' named entity 'Small molecules' named entity 'IL-6' named entity 'WHO' named entity 'acute kidney injury' named entity 'Th17' named entity 'JAKs' named entity 'Phosphorylated' named entity 'fever' named entity 'latent tuberculosis' named entity 'adipocytes' named entity 'IL-6' named entity 'rheumatoid arthritis' named entity 'oncology' named entity 'bronchoalveolar lavage fluid' named entity 'membrane-bound' named entity 'gp130' named entity 'SARS-CoV-2' named entity 'phase II study' named entity 'plaque psoriasis' named entity 'small molecule inhibitors' named entity 'high-risk' named entity 'COVID-19 disease' named entity 'Frederick, Maryland' named entity 'JAK1' named entity 'respiratory failure' named entity 'TNFα' named entity 'polyarticular' named entity 'GM-CSF' named entity 'cytokine' named entity 'CAR T cells'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software